NasdaqGS:PHATPharmaceuticals
Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative
Phathom Pharmaceuticals (PHAT) closed out FY 2025 with Q4 revenue of US$57.6 million and a basic EPS loss of US$0.29, as net income excluding extra items came in at a loss of US$21.1 million. Over recent quarters, the company has seen revenue move from US$29.7 million in Q4 2024 to US$57.6 million in Q4 2025, while quarterly basic EPS shifted from a loss of US$1.05 to a loss of US$0.29. This sets up a story where top line scale up is running ahead of bottom line profitability and keeps...